AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.
MetadataShow full item record
AbstractSmall cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease.
CitationTargeted therapies in small cell lung cancer: a review. 2010, 2 (1):25-37 Ther Adv Med Oncol
JournalTherapeutic Advances in Medical Oncology
- The development of targeted therapy in small cell lung cancer.
- Authors: Zhang Y, He J
- Issue date: 2013 Aug
- Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
- Authors: Sharp A, Bhosle J, Abdelraouf F, Popat S, O'Brien M, Yap TA
- Issue date: 2016 Jun
- [Molecular targeted therapies in small-cell lung cancer].
- Authors: Levy A, Malouf GG, Besse B, Massard C, Soria JC
- Issue date: 2010 May
- New targeted therapies and small-cell lung cancer.
- Authors: Rossi A, Maione P, Palazzolo G, Sacco PC, Ferrara ML, Falanga M, Gridelli C
- Issue date: 2008 Sep
- The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
- Authors: Horn L, Reck M, Spigel DR
- Issue date: 2016 Aug